🔗 Share this article

The recently developed medications for gonorrhoea in many years are being viewed as a "major milestone" in the effort against increasingly resistant strains of the bacteria, according to scientists.

A Global Challenge

The sexually transmitted infection are on the rise around the world, with data suggesting in excess of 82 million new cases per year. Especially elevated rates are observed in Africa and countries within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Within England, cases have reached a record high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune development in the face of growing infection rates, escalating drug resistance and the highly restricted available drugs presently on offer.”

Health officials are particularly alarmed about the rise in treatment-resistant strains. The World Health Organization has designated it as a "high-priority threat". A tracking program found that the effectiveness of standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Drugs Gain Clearance

Zoliflodacin, marketed under the name a brand name, was cleared by the US Food and Drug Administration in recent days for combating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Scientists anticipate that specific application of this new drug will help slow the emergence of superbugs.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, also received approval in the same week. This drug, which is employed against urinary tract infections, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin emerged from a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to see it through.

“This milestone represents a huge turning point in the management of highly resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Testing Results and Global Access

Based on findings released by a major medical journal, the new drug successfully treated the vast majority of genital gonorrhoea infections. This places it at an equal footing with the current standard treatment, which combines a dual-drug approach. The research enrolled nearly 1,000 participants from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, GARDP has the authority to register and commercialise the drug in many low-income and middle-income countries.

Clinicians treating patients have voiced optimism. Having a easy-to-administer therapy like this is hailed as a "game-changer" for managing the epidemic. This is deemed essential to reduce the burden of the illness for patients and to stop the proliferation of untreatable gonorrhoea around the world.